Introduction to the Theme “Novel Therapeutics with the Potential to Advance Health Care”

Literature Cited

1. 1.

   Saca VR, Burdette C, Sakmar TP. 2025.. GPCR biosensors to study conformational dynamics and signaling in drug discovery. . Annu. Rev. Pharmacol. Toxicol. 65::728
   [Google Scholar]
2. 2.

   Sriram K, Insel PA. 2018.. G protein–coupled receptors as targets for approved drugs: how many targets and how many drugs?. Mol. Pharmacol. 93::251–58
   [Crossref] [Google Scholar]
3. 3.

   McGonigle P. 2025.. How biologics have changed the drug discovery landscape. . Annu. Rev. Pharmacol. Toxicol. 65::2946
   [Google Scholar]
4. 4.

   Russell WMS, Burch RL. 1959.. The Principles of Humane Experimental Technique. London:: Methuen & Co.
   [Google Scholar]
5. 5.

   Maulana TI, Wevers NR, Kristoforus T, Chandler M, Lanz HL, et al. 2025.. Opportunities for microphysiological systems in toxicity testing of new drug modalities. . Annu. Rev. Pharmacol. Toxicol. 65::4769
   [Google Scholar]
6. 6.

   Yildrim Z, Swanson K, Wu X, Zou J, Wu J. 2025.. Next-gen therapeutics: pioneering drug discovery with iPSCs, genomics, AI, and clinical trials in a dish. . Annu. Rev. Pharmacol. Toxicol. 65::7190
   [Google Scholar]
7. 7.

   Abrahams E. 2008.. Right drug—right patient—right time: personalized medicine coalition. . Clin. Transl. Sci. 1::11–12
   [Crossref] [Google Scholar]
8. 8.

   Mosch R, van der Lee M, Guchelaar HJ, Swen JJ. 2025.. Pharmacogenetic panel testing: a review of current practice and potential for clinical implementation. . Annu. Rev. Pharmacol. Toxicol. 65::91109
   [Google Scholar]
9. 9.

   Empey PE, Karnes JH, Johnson JA. 2025.. Pharmacogenetics: opportunities for the All of Us research program and other large data sets to advance the field. . Annu. Rev. Pharmacol. Toxicol. 65::11130
   [Google Scholar]
10. 10.

    Elenbaas JS, Lee PC, Patel V, Stitziel NO. 2025.. Decoding the therapeutic target SVEP1: harnessing molecular trait GWASs to unravel mechanisms of human disease. . Annu. Rev. Pharmacol. Toxicol. 65::13148
    [Google Scholar]
11. 11.

    Delabays B, De Paoli C, Miller-Nesbitt A, Mooser V. 2025.. Genetically enriched clinical trials for precision development of noncancer therapeutics: a scoping review. . Annu. Rev. Pharmacol. Toxicol. 65::14967
    [Google Scholar]
12. 12.

    Chao AM, Taylor S, Moore M, Amaro A, Wadden TA. 2025.. Evolving approaches for pharmacological therapy of obesity. . Annu. Rev. Pharmacol. Toxicol. 65::16989
    [Google Scholar]
13. 13.

    Zhou Q, Li G, Hang K, Li J, Yang D, Wang M-W. 2025.. Weight loss blockbuster development: a role for unimolecular polypharmacology. . Annu. Rev. Pharmacol. Toxicol. 65::191213
    [Google Scholar]
14. 14.

    Sun Y, Hasbi A, George SR. 2025.. G protein–coupled receptor heteromers in brain: functional and therapeutic importance in neuropsychiatric disorders. . Annu. Rev. Pharmacol. Toxicol. 65::21536
    [Google Scholar]
15. 15.

    Menozzi E, Schapira AHV. 2025.. Prospects for disease slowing in Parkinson disease. . Annu. Rev. Pharmacol. Toxicol. 65::23758
    [Google Scholar]
16. 16.

    Wolf ME. 2025.. Targeting neuroplasticity in substance use disorders: implications for therapeutics. . Annu. Rev. Pharmacol. Toxicol. 65::25980
    [Google Scholar]
17. 17.

    Gilgenkrantz H, Al Sayegh R, Lotersztajn S. 2025.. Immunoregulation of liver fibrosis: new opportunities for antifibrotic therapy. . Annu. Rev. Pharmacol. Toxicol. 65::28199
    [Google Scholar]
18. 18.

    Deraison C, Vergnolle N. 2025.. Pharmacology of intestinal inflammation and repair. . Annu. Rev. Pharmacol. Toxicol. 65::30114
    [Google Scholar]
19. 19.

    Stagg J, Gutkind JS. 2025.. Targeting G protein–coupled receptors in immuno-oncological therapies. . Annu. Rev. Pharmacol. Toxicol. 65::31531
    [Google Scholar]
20. 20.

    Alves Costa Silva C, Fidelle M, Almonte AA, Derosa L, Zitvogel L. 2025.. Gut microbiota–related biomarkers in immuno-oncology. . Annu. Rev. Pharmacol. Toxicol. 65::33354
    [Google Scholar]
21. 21.

    Trepka KR, Olson CA, Upadhyay V, Zhang C, Turnbaugh PJ. 2025.. Pharma[e]cology: how the gut microbiome contributes to variations in drug response. . Annu. Rev. Pharmacol. Toxicol. 65::35573
    [Google Scholar]
22. 22.

    Wang L-Y, Hung C-L, Wang T-C, Hsu H-C, King H-J, Lin K-H. 2025.. PROTACs as therapeutic modalities for drug discovery in castration-resistant prostate cancer. . Annu. Rev. Pharmacol. Toxicol. 65::37596
    [Google Scholar]
23. 23.

    Cavazzana M, Corsia A, Brusson M, Miccio A, Semeraro M. 2025.. Treating sickle cell disease: gene therapy approaches. . Annu. Rev. Pharmacol. Toxicol. 65::397413
    [Google Scholar]
24. 24.

    Kelly ED, Ranek MJ, Zhang M, Kass DA, Muller GK. 2025.. Phosphodiesterases: evolving concepts and implications for human therapeutics. . Annu. Rev. Pharmacol. Toxicol. 65::41541
    [Google Scholar]
25. 25.

    Do TQ, Knollmann BC. 2025.. Inhibitors of intracellular RyR2 calcium release channels as therapeutic agents in arrhythmogenic heart diseases. . Annu. Rev. Pharmacol. Toxicol. 65::44363
    [Google Scholar]
26. 26.

    Gutiérrez JM, Casewell NR, Laustsen AH. 2025.. Progress and challenges in the field of snakebite envenoming therapeutics. . Annu. Rev. Pharmacol. Toxicol. 65::46585
    [Google Scholar]
27. 27.

    Shaw AA, Steketee JD, Bukiya AN, Dopico AM. 2025.. Toluene toxicity in the brain: from cellular targets to molecular mechanisms. . Annu. Rev. Pharmacol. Toxicol. 65::487506
    [Google Scholar]